Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.05.10
- Author:
Yuming WAN
1
;
Jing HUANG
2
;
Feng XU
1
Author Information
1. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Centrally;
Lung neoplasms;
Stereotactic body radiotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
pathology;
radiotherapy;
Humans;
Lung Neoplasms;
pathology;
radiotherapy;
Neoplasm Staging;
Radiotherapy;
instrumentation;
methods
- From:
Chinese Journal of Lung Cancer
2018;21(5):413-418
- CountryChina
- Language:Chinese
-
Abstract:
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure. This paper will review the definition, indication, dose regimens, dose-volume constraints for organs at risk, radiation technology, treatment side effect of centrally located NSCLC treated with SBRT and stereotactic body proton therapy.
